Enhancement of anti-diabetic effects of gliclazide using immediate release tablets in streptozotocin-induced diabetic and normal rats

Farmacia

Volumn 61, Issue 4, 2013, Pages 820-836

  Varshosaz, Jaleh ^a   Tavakoli, Naser ^a   Enteshary, Saideh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood glucose levels; Dissolution rate; Gliclazide; Streptozotocin induced diabetic rat

Indexed keywords

ALCOHOL; GLICLAZIDE; PROPYLENE GLYCOL; STARCH GLYCOLATE SODIUM; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; GLUCOSE BLOOD LEVEL; HUMIDITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; RAT; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET DISINTEGRATION TIME; WETTABILITY; HYDROPHILICITY; MEAN DISSOLUTION TIME; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TABLET THICKNESS;

EID: 84888173318     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jamzad S., Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-A technical note, APPS PharmSciTech, 2006; 7(2): E33.
2. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P. Biopharmaceutics classification system: the scientific basis for biowaiver extensions, Pharm Res, 2002; 19(7): 921-925.
3. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur J Pharm Biopharm, 2000; 50(1): 3-12.
4. Glowka F.K., Hermann T.W., Zabel M. Bioavailability of Gliclazide from some formulation tablets, Int J Pharm, 1998; 172 (1-2): 71-77.
5. Sweetman S.C. (34th ed), Martindale The Extra Pharmacopeia, Complate Drug Reference, Pharmaceutical Press, London, 2007.
6. Seedher N., Kanojia M. Co-solvent solubilization of some poorly-soluble antidiabetic drugs, Pharm Dev Technol, 2009; http://www.informaworld.com/smpp/title~db=all~content= t713597289~tab=issueslist~branches=14-v1414 (2): 185-192.
7. Patil M.P., Gaikwad N.J. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions, Acta Pharm, 2009; 59(1): 57-65.
8. Sapkal N.P., Kilor V.A., Bhursari K.P., Daud A.S. Evaluation of some method for preparing gliclazide-β-cyclodextrin inclusion complexes, Tropical J Pharm Res, 2007; 6(4): 833-840.
9. Talari R, Varshosaz J, Mostafavi A, Nokhodchi A, Development and validation of a novel RP-HPLC method for pharmacokinetic studies of gliclazide in rat, Farmacia, 2011, 59(3), 388-395
10. Palmer K.J., Brogden R.N. Gliclazide on update of its pharmacological properties and therapeutic efficacy in NIDDM, Drugs, 1993; 46(1): 92-125.
11. Hong S.S., Lee S.H., Lee Y.J., Chung S.J., Lee M.H., Shim C.K. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide, J Control Rel, 1998; 51(2-3): 185-192.
12. Varshosaz J., Talari R., Mostafavi S.A., Nokhodchi A. Dissolution enhancement of gliclazide using in-situ micronization by solvent change method. Powder Technol, 2008;187(3): 222-230.
13. Higuchi T., Connors K.A. Phase-solubility Techniques, Adv Anal Chem Instr, 1965; 4: 17-212.
14. El-kamel A.H., Sokar M.S., Al Gamal S.S., Naggar V.F. Preparation and evaluation of ketoprofen floating oral delivery system, Int J Pharm, 2001;.220: 13-21.
15. Javadzadeh Y., Siahi M.R., Asnaashari S., Nokhodchi A. An investigation of physicochemical properties of piroxicam liquisolid compacts, Pharm Dev Technol, 2007;12(3): 337-43.
16. El-Enany N. Spectrophotometric Determination of gliclazide in pharmaceuticals and biological fluids through ternary complex formation with eosin and palladium (II), Farmaco, 2004; 59(1): 63-69.
17. Velescu BŞ, Uivaroşi V, Negreş S, Effect of di-μ-hydroxo-bis (quercetinato oxovanadium(iv) complex on alloxan-induced diabetic rats, Farmacia, 2012, 60(5), 696-710
18. 2 and sd for development of diltiazem HCl modified-release tablets using a 32 factorial design, Drug Dev Ind Pharm, 2002; 28(1): 77-87.
19. Prasad S.K., Kulshreshtha A., Qureshi T.N. Antidiabetic activity of some herbal plants in streptozotocin induced diabetic albino rats, Pak J Nutr, 2009; 8(5): 551-557.
20. Eidi A., Eidi M., Sokhteh M. Effect of fenugreek (Trigonella foenum graecum L) seeds on serum parameters in normal and streptozotocin-induced diabetic rats. Nutr Res, 2007;27(11): 728-733.
21. Thomas L. (1st ed), Clinical Laboratory Diagnostics, TH-books, Veriagsgseller Chaft, 1998.
22. Madaras-Kelly K.J., Ostergaard B.E., Baeker H.L., Rotschafer J.C. Twenty-four-hour area under the concentration-time curve /MIC ratio as a generic predictor of fluoroquin-olone antimicrobial effect by using three strain of pseudomonas aeruginosa and an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 1996; 40(30): 627-632.
23. Noyes A., Whitney W. R. The rate of solution of solid substances in their own solutions, J Am Chem Soc, 1897; 19: 930-934.
24. Aggarwal S., Singh P.N., Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes, Pharmazie, 2002;57(3): 191-3.
25. Talari R., Varshosaz J., Mostafavi S.A., Nokhodchi A. Dissolution enhancement of gliclazide using pH change approach in presence of twelve stabilizers with various physicochemical properties, J Pharm Pharm Sci, 2009; 12(3): 250-265.
26. Talari R., Varshosaz J., Mostafavi S.A., Nokhodchi A. Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats. AAPS PharmSciTech, 2010; 11(2): 786-92.
27. Rowe R.C., Sheskey P.J., Weller P.J. (4th ed), Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington DC, 2003; 104.
28. Pulido N., Suarez A., Casanova B., Romero R., Rodriguez E., Rovira A. Gliclazide treatment of streptozotocin diabetic rats restores glut4 protein content and basal glucose uptake in skeletal muscle, Metabolism, 1997; 46(Suppl 1): 10-13.
29. Qiang X., Satoh J., Sagara M., Fukuzawa M., Masuda T., Miyaguchi S., Takahashi K., Toyota T. Gliclazide inhibits diabetic neurophathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats, Metabolism, 1998; 47(8): 977-981.
30. Ma A., Kamp M., Bird D., Howlett V., Cameron D.P. The effects of long term gliclazide administration on insulin secretion and insulin sensitivity, Aust NZ J Med, 1989; 19(1): 44-9.
31. Della Casa L., del Rio G., Glaser B., Cerasi E. Effect of 6-month gliclazide Treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin-induced normoglycemia, Diabetes Res Clin Pract, 1991; 14(Suppl 2), S69-78.